For those seeking to potentially manage symptoms of this condition, Regenerative Medicine for Lupus is a natural alternative option.
Lupus is a chronic autoimmune disease that can affect nearly any organ in the body.
When the immune system, which normally protects against infection, starts attacking healthy tissues, widespread inflammation and tissue damage can occur.
The most common form is Systemic Lupus Erythematosus (SLE).
Because lupus can look different from person to person, symptoms may range from mild fatigue to severe organ involvement.
Common Symptoms Include:
People often experience flares, periods when symptoms worsen, followed by times of remission when symptoms ease.
The following are potential symptom improvements with Regenerative Medicine:
Medical Review: Dr. Gerald Mastaw, MD – Board-Certified Physician Last Updated: October 2025
2025 – Double-Blind RCT Using MSC Secretome
Title: Umbilical Cord MSC-Derived Secretome as a Potential Treatment for SLE: A Double-Blind Randomized Controlled Trial
Journal: Stem Cell Research & Therapy – Full Text
Summary:
Twenty-nine women with active lupus received weekly injections of MSC-secretome (the bioactive solution produced by MSCs) or placebo for six weeks.
Patients receiving MSC-secretome had significant reductions in lupus disease activity scores and improved immune markers such as complement C3 and lower inflammatory cytokines (IL-6, TNF-α).
The treatment was safe and well-tolerated, with no severe adverse events.
2025 – Meta-Analysis Across Autoimmune Diseases (Including Lupus)
Title: Efficacy and Safety of MSC Transplantation in Autoimmune and Rheumatic Diseases
Journal: Stem Cell Research & Therapy – Full Text
Summary:
This large review analyzed 42 randomized trials (2,183 patients).
In lupus subgroups, MSC therapy significantly lowered SLE Disease Activity Index (SLEDAI) scores (SMD ≈ –2.32, p=0.0003).
No increase in adverse events was found versus controls.
Researchers concluded MSC therapy is safe and shows measurable improvement in lupus disease activity.
2024 – Phase 1 Dose-Escalation Trial in France
Title: Allogeneic UC-MSC Therapy for Refractory Lupus: A Phase 1 Study
Journal: PubMed Central – Full Text
Summary:
Eight patients with severe, treatment-resistant lupus received escalating doses of UC-MSCs (2–4 million cells/kg).
Treatment was well-tolerated, with only mild transient infusion reactions in two participants.
Over a year of follow-up, disease activity stabilized or improved, supporting safety even at higher doses.
2022 – Phase 1 UC-MSC Trial for Refractory SLE
Title: Safety, Immunologic Effects, and Clinical Response of UC-MSCs in SLE
Journal: Frontiers in Immunology – Full Text
Summary:
Six patients with active lupus unresponsive to medication received a single UC-MSC infusion (1×10⁶ cells/kg).
By 24 weeks, 83% achieved the lupus responder endpoint (SRI-4), showing reduced disease activity and normalization of B-cell profiles.
No serious side effects occurred.
The trial concluded UC-MSC infusion was safe and associated with meaningful clinical improvement.
Regenerative Medicine is still considered an experimental procedure and not approved by the FDA. Patients must consider realistic expectations in their research and possible therapy options.
You may wish to explore regenerative options if you:
At Stemedix, we focus on patient-centered regenerative medicine backed by emerging clinical evidence. Our team reviews your medical history, current treatment, and goals to determine whether regenerative medicine approaches could be a safe adjunctive path forward.
This page is for educational purposes only and does not constitute medical advice.
Stem cell and secretome-based treatments for lupus are not FDA-approved, and outcomes vary by individual.
Always consult a licensed rheumatologist or qualified healthcare provider before making treatment decisions.
He L. et al. Safety and Immune Response of UC-MSCs in Refractory SLE. Front Immunol., 2022. Full Text
Speak with a Care Coordinator today for a more accurate assessment of your condition and therapy options.
Stemedix speaks with Patricia about her experience with Stemedix stem cell treatment for Lupus.
Our Board-Certified Physicians specialize in regenerative medicine. They stay abreast of the latest developments in stem cell research. Each patient is screened and reviewed before being approved for therapy.
Each patient is thoroughly reviewed to ensure their safety for treatment. The physicians will then determine potential benefit candidacy. If approved, a customized treatment plan is offered for the patient.
Stemedix can help coordinate patients with necessary wheelchair transportation, medical equipment, and Care Giving services as needed during their stay. Your Care Coordinator is available for questions and assistance.
Spinal cord injury (SCI) is a serious neurological condition that can disrupt communication between the brain and body. Depending on the severity and location of the injury, patients may experience changes in movement, sensation, autonomic function, bladder or bowel control, and overall independence. Because damage to the spinal cord can involve both the initial physical…
Chronic wounds are wounds that do not move through the normal stages of healing as expected. Instead of closing properly, they may remain open for months, creating ongoing pain, infection risk, limited mobility, and reduced quality of life. Common examples include diabetic foot ulcers, pressure ulcers, venous leg ulcers, and wounds that develop after radiation…
Mesenchymal stem cells (MSCs) have become one of the most widely studied tools in regenerative medicine because of their ability to support tissue repair, regulate inflammation, and communicate with damaged or stressed cells. These cells are being explored across a wide range of conditions, including inflammatory disorders, neurological disease, cardiovascular injury, lung disease, wound healing,…
Contact us today and let Stemedix provide professional service accompanied by one of our Care Coordinators to ensure you have the best experience possible!